Off-label prescribing patterns of antidepressants in children and adolescents

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 137-144

  Lee, Euni ^a   Teschemaker, Anna R ^b   Johann Liang, Rosemary ^c   Bazemore, Gina ^d   Yoon, Martin ^e   Shim, Kye Sik ^f   Daniel, Marlon ^a   Pittman, Jerome ^a   Wutoh, Anthony K ^a  

^a HOWARD UNIVERSITY   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d Montgomery General Hospital   (United States)

^e INDIAN HEALTH SERVICE   (United States)

^f Kyung Hee University Hospital   (South Korea)

Author keywords

Ambulatory care; Antidepressants; National survey; Pediatric depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; AFFECTIVE PSYCHOSIS; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILD; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG INDICATION; FEMALE; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; NOCTURNAL ENURESIS; OBSESSIVE COMPULSIVE DISORDER; PEDIATRICIAN; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHOOL CHILD;

ADOLESCENT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856288042     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2145     Document Type: Article

References (36)

1. Zito JM, Safer DJ, DosReis A, et al. Psychotropic practice for youths. Arch Pediatr Adolesc Med 2003; 157: 17-25.
2. Thomas CD, Conrad P, Casler R, et al. Trends in the use of psychotropic medications among adolescents, 1994-2001. Psychiatr Serv 2006; 57(10): 68-69.
3. Zito JM, Tobi H, Lolkje TW, et al. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 2006; 15: 793-798.
4. Zito JM, Safer DJ, DosReis A, et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002; 109(5): 727-727.
5. FDA Public Health Advisory. Suicidality in Children and Adolescents being treated with Antidepressant Medications, October 15, 2004. FDA/Center for Drug Evaluation and Research, Department of Health and Human Services, 2009. [16 November 2009].
6. Committee on Drugs, American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics 2002; 110: 181-183.
7. Shirkey H. Therapeutic orphans. J Pediatr 1968; 72: 119-120.
8. Wilson JT. Pragmatic assessment of medicines available for young children and pregnant or breast-feeding women. In Basic and Therapeutic Aspects of Perinatal Pharmacology, Morselli PL, Garattini S, Sereni F (eds.). Raven Press: New York, NY, 1975; pp. 411-421.
9. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161(3): 282-290.
10. Efron D, Hiscock H, Sewell JR, et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003; 111(2): 372-375.
11. Hugtenburg JG, Heerdink ER, Tso YH. Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatr 2005; 94(10): 1484-1487.
12. Zito JM, Derivan AT, Kratochvil CJ, et al. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008; 2: 24.
13. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Rep 2008; 6(8): 1-29.
14. US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Ambulatory Health Care Data. [20 September 2007].
15. Micromedex. Micromedex® Healthcare Series [Internet database]. Thomson Micromedex: Greenwood Village, Colorado, 2006.
16. Drugs@FDA. Label and approval history. [2 December 2009].
17. Ma J, Lee K-V, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005; 37: 434-442.
18. Mojtabai R. Diagnosing depression and prescribing antidepressants by primary care physicians: the impact of practice style variations. Ment Health Serv Res 2002; 4: 109-118.
19. Blumer JL. Off-label uses of drugs in children. Pediatrics 1999; 104(3 Pt 2): 598-602.
20. Cote CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the "therapeutic orphan" about to be adopted? Pediatrics 1996; 98(1): 118-123.
21. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling. JAMA 2003; 290: 905-911.
22. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79-82.
23. Bazzan ATF, Mangione-Smith R, Schonlau M, et al. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009; 9(2): 81-88.
24. Ekin-Daukins S, Helms P, Simpson Colin, et al. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004; 60(5): 349-353.
25. Edersheim JG. Off-label prescribing: risk management. Psychiatr Times 2009; 26(4): 12-15.
26. Guiton S, Reith DM, Isitt VL .Off label prescribing in children. BMJ 2002; 325: 338.
27. Radley DC, Finkelstein SN Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.
28. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004; 42(12): 1176-1185.
29. Kravitz RL, Epstein RM, Feldman MD et al. Influence of patients requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005; 293(16): 1995-2002.
30. Shashi K, Bhatia MD, Subhash C, et al. Childhood and adolescent depression. Am Fam Physician 2007; 75(1): 73-80.
31. Dell ML, Vaughan BS, Kratochvil CJ. Ethics and the prescription pad. Child Adolesc Psychiatr Clin N Am 2008; 17: 93-111.
32. Meyer RJ. Off-label prescribing: an FDA official's perspective. [17 May 2010].
33. Curtiss FR, Fairman KA. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department. JMCP 2009; 15: 161-165.
34. Schultheis LW, Mathis LL, Roca RA. Pediatric drug development in anesthesiology: an FDA perspective. Anesth Analg 2006; 103: 49-51.
35. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ. Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol 2008; 18(1): 70-80.
36. Jong GW, Volto AG, Hoog M, et al. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001; 108: 1089-1093.